Engineered immune cells take on liver cancer in new trial

NCT ID NCT04864054

Recruiting now Disease control Sponsor: Eureka Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new treatment called ECT204 for adults with advanced liver cancer that has not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The trial will enroll 60 people to check if the therapy is safe and whether it can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ECT204 T cells (a type of immune cell therapy made from the patient's own blood)
What this could lead to: If it works, this could offer a new treatment option for people with advanced liver cancer who have run out of standard therapies.
What could go wrong: This is an early-phase trial with only 60 participants, so the therapy may not work or could cause serious side effects. It is not a cure and long-term safety is unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma liver and intrahepatic bile duct neoplasm liver cancer Liver Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA LIVER CANCER, ADULT LIVER NEOPLASM METASTATIC LIVER CANCER

Contacts and locations

Locations

City of Hope
RECRUITING

Duarte, California, 91010, United States
Fred Hutchinson Cancer Center, University of Washington
RECRUITING

Seattle, Washington, 98109, United States
Kansas University Medical Center, Principal Investigator:
COMPLETED

Westwood, Kansas, 66205, United States
Montefiore Einstein Comprehensive Cancer Center
RECRUITING

The Bronx, New York, 10467, United States
National Taiwan University Cancer Center
RECRUITING

Taipei, 106, Taiwan
Oregon Health and Sciences University
RECRUITING

Portland, Oregon, 97239, United States
Roswell Park Comprehensive Cancer Center
COMPLETED

Buffalo, New York, 14263, United States
University of Texas Southwestern, Harold C. Simmons Comprehensive Cancer Center
RECRUITING

Dallas, Texas, 75235, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.